Shares of Canadian biotech Aeterna Zentaris plummeted nearly 56% on 6 November after the FDA rejected the company's new drug application (NDA) for Macrilen (macimorelin acetate), an ghrelin agonist, for use in evaluating adult growth hormone deficiency (AGHD).
Aeterna Zentaris tanks on FDA Macrilen rejection
Shares of Canadian biotech Aeterna Zentaris plummeted nearly 56% on 6 November after the FDA rejected the company's new drug application (NDA) for Macrilen (macimorelin acetate), an ghrelin agonist, for use in evaluating adult growth hormone deficiency (AGHD).
More from Alimentary/Metabolic
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.